{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:36:37Z","timestamp":1768494997998,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY419"],"award-info":[{"award-number":["2022KY419"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.acvd.2025.06.077","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:17:12Z","timestamp":1756826232000},"page":"643-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overall safety evaluation of the risk signals of sacubitril\/valsartan: A postmarketing pharmacoepidemiology study from 2015 to 2024"],"prefix":"10.1016","volume":"118","author":[{"given":"Xiangyu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.acvd.2025.06.077_bib0170","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.acvd.2025.06.077_bib0175","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1002\/ehf2.14097","article-title":"Sacubitril\/valsartan in heart failure: efficacy and safety in and outside clinical trials","volume":"9","author":"Abdin","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.acvd.2025.06.077_bib0180","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"issue":"6\u20137","key":"10.1016\/j.acvd.2025.06.077_bib0185","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.acvd.2024.04.003","article-title":"Sacubitril\/valsartan has an underestimated impact on the right ventricle in patients with sleep-disordered breathing, especially central sleep apnoea syndrome","volume":"117","author":"Cardelli","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.06.077_bib0190","doi-asserted-by":"crossref","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","article-title":"A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system","volume":"14","author":"Fang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.acvd.2025.06.077_bib0195","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.acvd.2025.06.077_bib0200","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"9","key":"10.1016\/j.acvd.2025.06.077_bib0205","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1111\/cns.14195","article-title":"Updated insights on dementia-related risk of sacubitril\/valsartan: a real-world pharmacovigilance analysis","volume":"29","author":"Chen","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.acvd.2025.06.077_bib0210","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2020.08.067","article-title":"Angioedema with sacubitril\/valsartan: trial-level meta-analysis of over 14,000 patients and real-world evidence to date","volume":"323","author":"Dani","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2025.06.077_bib0215","doi-asserted-by":"crossref","first-page":"131613","DOI":"10.1016\/j.ijcard.2023.131613","article-title":"The real-world safety of sacubitril\/valsartan among older adults (\u226575): a pharmacovigilance study from the FDA data","volume":"397","author":"Lerman","year":"2024","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.acvd.2025.06.077_bib0220","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","article-title":"Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2025.06.077_bib0225","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of Olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.acvd.2025.06.077_bib0230","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.acvd.2025.06.077_bib0235","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","article-title":"Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database","volume":"354","author":"Lu","year":"2024","journal-title":"J Affect Disord"},{"issue":"3","key":"10.1016\/j.acvd.2025.06.077_bib0240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.acvd.2025.06.077_bib0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.acvd.2025.06.077_bib0250","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.acvd.2025.06.077_bib0255","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.acvd.2025.06.077_bib0260","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to Sacubitril\/Valsartan or Enalapril in the PIONEER-HF Trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.acvd.2025.06.077_bib0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14779072.2024.2354255","article-title":"Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis","volume":"22","author":"Park","year":"2024","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"10.1016\/j.acvd.2025.06.077_bib0270","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10557-021-07210-1","article-title":"Five years of Sacubitril\/Valsartan-a safety analysis of randomized clinical trials and real-world pharmacovigilance","volume":"36","author":"Kim","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2025.06.077_bib0275","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"11","author":"Mcmurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.acvd.2025.06.077_bib0280","doi-asserted-by":"crossref","first-page":"e004745","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.acvd.2025.06.077_bib0285","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13318-016-0328-3","article-title":"Pharmacokinetics, safety and tolerability of sacubitril\/valsartan (LCZ696) after single-dose administration in healthy Chinese subjects","volume":"42","author":"Han","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1016\/j.acvd.2025.06.077_bib0290","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjoto.2010.11.014","article-title":"Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis","volume":"32","author":"Shino","year":"2011","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"10.1016\/j.acvd.2025.06.077_bib0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.athoracsur.2016.10.021","article-title":"Angiotensin receptor blockade improves cardiac surgical outcomes in patients with metabolic syndrome","volume":"104","author":"Manning","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.acvd.2025.06.077_bib0300","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0897190019842700","article-title":"Psychiatric manifestations with Sacubitril\/Valsartan: a case report","volume":"33","author":"Wooster","year":"2020","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.acvd.2025.06.077_bib0305","doi-asserted-by":"crossref","first-page":"173851","DOI":"10.1016\/j.ejphar.2021.173851","article-title":"Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!","volume":"894","author":"Poorgolizadeh","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.acvd.2025.06.077_bib0310","doi-asserted-by":"crossref","first-page":"111363","DOI":"10.1016\/j.mad.2020.111363","article-title":"Neprilysin expression and functions in development, ageing and disease","volume":"192","author":"Nalivaeva","year":"2020","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"10.1016\/j.acvd.2025.06.077_bib0315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/BJ20120653","article-title":"Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?","volume":"446","author":"Teich","year":"2012","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.acvd.2025.06.077_bib0320","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.acvd.2025.06.077_bib0325","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition - implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.acvd.2025.06.077_bib0330","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fnmol.2019.00234","article-title":"The dual role of Kinin\/Kinin receptors system in Alzheimer's disease","volume":"12","author":"Ji","year":"2019","journal-title":"Front Mol Neurosci"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625004437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625004437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:41:44Z","timestamp":1768441304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213625004437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1875213625004437"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2025.06.077","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall safety evaluation of the risk signals of sacubitril\/valsartan: A postmarketing pharmacoepidemiology study from 2015 to 2024","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2025.06.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}